ERBB2 and breast cancer: These data were consistent with the results of the in vitro experiments, indicating that the immunoapoptotic molecules DFF40‐scFv, Cytc‐scFv and 3Cytc‐scFv showed targeted suppression of HER‐2+ breast cancer cells in vivo.